Company / Return on Assets (ROA)
KalVista Pharmaceuticals, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-73.2%
FY2025
5-year range
-77.9% / -30.3%
FY2021-FY2025
Trend
+6.1%
vs FY2024
Sector context
#198 of 213
Health Care
What the data says
Among 213 Health Care companies, KalVista Pharmaceuticals, Inc. is in the bottom 7% for return on assets (roa). Return on Assets (ROA) returned to growth in FY2025 after 3 years of decline, reaching -73.2%.
Based on SEC 10-K filings.
-73.2% in FY2025 with a 5-year CAGR of -23.2%.
Declined from -69.1% to -73.2% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -27.6pp
- 5-Year Change
- -23.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 213This company -73.2% Sector average -24.2%
▼
-202.7% below sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 6.1% year-over-year.
- Currently 49.0pp below the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2019.
- Lowest return on assets (roa) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -73.2% | +6.1% |
| FY2024 | -77.9% | -12.7% |
| FY2023 | -69.1% | -51.7% |
| FY2022 | -45.6% | -50.5% |
| FY2021 | -30.3% | +39.4% |
| FY2020 | -50.0% | -217.3% |
| FY2019 | -15.8% | +15.5% |
| FY2018 | -18.6% | +59.5% |
| FY2017 | -46.0% | +38.8% |
| FY2016 | -75.2% | -273.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026